CO5630030A2 - Acido 4-(acetilamino)-3-{(4-clorofenil)tio}-2-metil-1h-indol-1-acetico y composicion farmaceutica que lo contiene - Google Patents

Acido 4-(acetilamino)-3-{(4-clorofenil)tio}-2-metil-1h-indol-1-acetico y composicion farmaceutica que lo contiene

Info

Publication number
CO5630030A2
CO5630030A2 CO05118882A CO05118882A CO5630030A2 CO 5630030 A2 CO5630030 A2 CO 5630030A2 CO 05118882 A CO05118882 A CO 05118882A CO 05118882 A CO05118882 A CO 05118882A CO 5630030 A2 CO5630030 A2 CO 5630030A2
Authority
CO
Colombia
Prior art keywords
optionally substituted
halogen
independently selected
heteroaryl
aryl
Prior art date
Application number
CO05118882A
Other languages
English (en)
Inventor
Roger Bonnert
Rukhsana Rasul
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5630030A2 publication Critical patent/CO5630030A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto de formula (I) o una sal farmacéuticamente aceptable o solvato de este: en la cual:R1 es uno o más sustituyentes seleccionados independientemente de NR4SO2R5, NR4CO2R6, NR4COR6, NR4SO2NR5R6, NHSO2R5, NHCO2R6, NHCOR6, NHCONR4, NHSO2NR5R6, o heteroarilo, el último puede estar opcionalmente sustituido por halógeno, CN, OR7, alquilo C1-3 (que puede estar opcionalmente sustituido por átomos de halógeno);R2 es hidrógeno, halógeno, CN, SO2R4 o CONR5R6, CH2OH, CH2OR4 o alquiloC1-7, estando el ultimo grupo opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente de átomos de halógeno, OR8 y NR5R6, S(O)xR7, en donde x es 0, 1 o 2;R3 es arilo o heteroarilo, cada uno de los cuales está opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente de hidrógeno, halógeno, CN, OH, SO2R4, OR4, SR4, SOR4, SO2NR5R6, CONR5R6, NR5R6, NHSO2R4, NHCOR4, NHCO2R4, NR7SO2R4, NR7CO2R4, NR7COR4, alqueniloC2-C6, alquiniloC2-C6, alquiloC1-6, estando los últimos tres grupos opcionalmente sustituidos por uno o más sustituyentes seleccionados independientemente de átomos de halógeno, OR8 y NR5R6, S(O)xR7, en donde x es 0, 1 o 2;R4 representa arilo, heteroarilo, o alquiloC1-6, todos los cuales pueden estar opcionalmente sustituidos por uno o más sustituyentes seleccionados independientemente de átomos de halógeno, arilo, heteroarilo, OR10, OH, NR11R12, S(O)xR13 (en donde x es 0, 1 o 2), CONR14R15, NR14COR15, SO2NR14R15, NR14SO2R15, CN, nitro;R5 y R6 representan independientemente un átomo de hidrógeno, un grupo alquiloC1-6, o un arilo, o un heteroarilo, los últimos tres pueden estar opcionalmente sustituidos por uno o más sustituyentes seleccionados independientemente de átomos de halógeno, arilo, OR8 y NR14R15, CONR14R15, NR14COR15, SO2NR14R15, NR14SO2R15; CN, nitro, alquilo C1-3 (que puede estar opcionalmente sustituido por átomos de halógeno;oR5 y R6 junto con el átomo de nitrógeno al cual están unidos pueden formar un anillo heterocíclico saturado de 3-8 miembros que contiene opcionalmente uno o más átomos seleccionados de O, ...
CO05118882A 2003-05-27 2005-11-23 Acido 4-(acetilamino)-3-{(4-clorofenil)tio}-2-metil-1h-indol-1-acetico y composicion farmaceutica que lo contiene CO5630030A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301569A SE0301569D0 (sv) 2003-05-27 2003-05-27 Novel compounds
SE0302305A SE0302305D0 (sv) 2003-05-27 2003-08-27 Novel Compounds

Publications (1)

Publication Number Publication Date
CO5630030A2 true CO5630030A2 (es) 2006-04-28

Family

ID=33492578

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05118882A CO5630030A2 (es) 2003-05-27 2005-11-23 Acido 4-(acetilamino)-3-{(4-clorofenil)tio}-2-metil-1h-indol-1-acetico y composicion farmaceutica que lo contiene

Country Status (31)

Country Link
US (4) US7687535B2 (es)
EP (3) EP2025670B1 (es)
JP (2) JP4541361B2 (es)
KR (3) KR20110050754A (es)
CN (2) CN102391171A (es)
AR (1) AR044552A1 (es)
AT (3) ATE425965T1 (es)
AU (1) AU2004242624B2 (es)
BR (1) BRPI0410711B8 (es)
CA (1) CA2526866C (es)
CO (1) CO5630030A2 (es)
CY (3) CY1109104T1 (es)
DE (2) DE602004020072D1 (es)
DK (3) DK2281815T3 (es)
ES (3) ES2361485T3 (es)
HK (3) HK1090635A1 (es)
HR (3) HRP20090281T1 (es)
IL (4) IL171928A (es)
IS (2) IS2722B (es)
MX (1) MXPA05012680A (es)
MY (1) MY144483A (es)
NO (1) NO20056130L (es)
NZ (1) NZ543722A (es)
PL (3) PL2025670T3 (es)
PT (3) PT2025670E (es)
RU (1) RU2361860C2 (es)
SE (2) SE0301569D0 (es)
SI (3) SI2025670T1 (es)
TW (2) TWI328004B (es)
WO (1) WO2004106302A1 (es)
ZA (1) ZA200509598B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
NZ550365A (en) 2004-03-11 2010-09-30 Actelion Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
PL1833791T3 (pl) 2004-12-27 2011-12-30 Actelion Pharmaceuticals Ltd Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
ES2369714T3 (es) 2005-04-21 2011-12-05 Merck Serono Sa Pirazina sulfonamidas 2,3 sustituidas como inhibidores de crth2.
RU2478639C2 (ru) 2005-05-24 2013-04-10 Лаборатуар Сероно С.А. Трициклические спиро-производные в качестве модуляторов crth2
EP2397476A3 (en) 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Indole derivative having PGD2 receptor antagonist activity
EP1911759A4 (en) 2005-07-22 2010-07-21 Shionogi & Co AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
AU2006296397B2 (en) * 2005-09-30 2011-12-15 Gb001, Inc. Quinolines and their therapeutic use
CN102558021A (zh) * 2006-05-26 2012-07-11 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
DK2037967T3 (en) 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
RU2458918C2 (ru) * 2006-07-22 2012-08-20 Оксаген Лимитед Соединения, обладающие антагонистической активностью по отношению к crth2
PL2051962T3 (pl) 2006-08-07 2012-03-30 Actelion Pharmaceuticals Ltd Pochodne kwasu (3-amino-1,2,3,4-tetrahydro-9h-karbazol-9-ilo)-octowego
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
JP2010530425A (ja) * 2007-06-21 2010-09-09 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストの粒子
UA101326C2 (en) * 2007-06-21 2013-03-25 Актимис Фармасьютикалз, Инк. Amine salts of crth2 antagonist
CA2707785C (en) 2007-12-14 2015-11-03 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US20110312945A1 (en) * 2008-10-01 2011-12-22 James Jia Crth2 modulators
US8273769B2 (en) 2009-02-12 2012-09-25 Merck Serono Sa Phenoxy acetic acid derivatives
WO2011004182A1 (en) * 2009-07-06 2011-01-13 Astrazeneca Ab Intermediates and processes for the preparation of 4- (acetylamino) ) -3- [ (4-chloro-phenyl) thio] -2-methyl-1h-indole-1-acetic acid
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
US9032565B2 (en) 2009-12-16 2015-05-19 Kohler Co. Touchless faucet assembly and method of operation
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
CN102791689B (zh) 2010-03-22 2014-10-29 埃科特莱茵药品有限公司 3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
KR101928595B1 (ko) 2011-04-14 2018-12-12 이도르시아 파마슈티컬스 리미티드 7-(헤테로아릴-아미노)-6,7,8,9-테트라히드로피리도［1,2-ａ］인돌 아세트산 유도체 및 프로스타글란딘 ｄ2 수용체 조절자로서의 이의 용도
EA026456B1 (ru) 2011-12-16 2017-04-28 Атопикс Терапьютикс Лимитед Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
JP6193968B2 (ja) 2012-03-21 2017-09-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 発毛を調節するための組成物および方法
CA2886117C (en) * 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Indoline compounds and their use as aldosterone synthase inhibitors
PE20151997A1 (es) * 2013-03-15 2016-01-13 Plexxikon Inc Compuestos heterociclicos y usos de los mismos
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2014190199A1 (en) * 2013-05-24 2014-11-27 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
HUE039614T2 (hu) 2014-03-17 2019-01-28 Idorsia Pharmaceuticals Ltd Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk
ES2699379T3 (es) 2014-03-18 2019-02-11 Idorsia Pharmaceuticals Ltd Derivados de ácido azaindol acético y su uso como moduladores del receptor de prostaglandina D2
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2017019858A1 (en) 2015-07-30 2017-02-02 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2
ES2867757T3 (es) 2015-09-15 2021-10-20 Idorsia Pharmaceuticals Ltd Formas cristalinas
CA3079029A1 (en) 2017-10-13 2019-04-18 Plexxikon Inc. Solid forms of a compound for modulating kinases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
AU6254294A (en) 1993-02-24 1994-09-14 Merck & Co., Inc. Inhibitors of hiv reverse transcriptase
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
WO1999009007A1 (en) 1997-08-21 1999-02-25 American Home Products Corporation Solid phase synthesis of 2,3-disubstituted indole compounds
DE69814012T2 (de) 1997-12-19 2004-04-01 Eli Lilly And Co., Indianapolis Hypoglykàmische imidazoline derivate
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
WO2001032621A1 (fr) * 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif
EA005212B1 (ru) 1999-12-24 2004-12-30 Авентис Фарма Лимитед Азаиндолы
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
EP1301497A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
JP4595182B2 (ja) * 2000-09-07 2010-12-08 ソニー株式会社 情報記録装置、情報再生装置、情報記録方法、情報再生方法、および情報記録媒体、並びにプログラム提供媒体
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
PL373410A1 (en) 2002-02-01 2005-08-22 F.Hoffman-La Roche Ag Substituted indoles as alpha-1 agonists
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
JP2007508363A (ja) 2003-10-14 2007-04-05 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
CN102558021A (zh) 2006-05-26 2012-07-11 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
CA2654026A1 (en) 2006-06-08 2007-12-13 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
EP2040688B1 (en) 2006-06-28 2014-04-02 Sanofi New cxcr2 inhibitors

Also Published As

Publication number Publication date
NZ543722A (en) 2007-05-31
RU2005137403A (ru) 2006-05-27
JP2010155862A (ja) 2010-07-15
CN1795174A (zh) 2006-06-28
IL212371A0 (en) 2011-06-30
EP2281815B1 (en) 2012-04-04
PT1656346E (pt) 2009-05-20
WO2004106302A1 (en) 2004-12-09
BRPI0410711B8 (pt) 2021-05-25
DE602004031894D1 (de) 2011-04-28
HRP20120390T1 (hr) 2012-06-30
DK2025670T3 (da) 2011-06-06
AU2004242624A1 (en) 2004-12-09
SI2025670T1 (sl) 2011-06-30
ZA200509598B (en) 2006-12-27
PL2281815T3 (pl) 2012-08-31
AR044552A1 (es) 2005-09-21
US7687535B2 (en) 2010-03-30
SI2281815T1 (sl) 2012-06-29
BRPI0410711B1 (pt) 2018-09-25
CA2526866A1 (en) 2004-12-09
TW201024261A (en) 2010-07-01
DK2281815T3 (da) 2012-06-18
IL194872A0 (en) 2011-08-01
MY144483A (en) 2011-09-30
JP4541361B2 (ja) 2010-09-08
PT2281815E (pt) 2012-05-24
MXPA05012680A (es) 2006-02-08
BRPI0410711A (pt) 2006-06-13
ATE502010T1 (de) 2011-04-15
IS8189A (is) 2005-12-20
US20080249110A1 (en) 2008-10-09
US20110263614A1 (en) 2011-10-27
KR20110050754A (ko) 2011-05-16
IL212265A0 (en) 2011-06-30
EP2025670B1 (en) 2011-03-16
ES2361485T3 (es) 2011-06-17
CY1111469T1 (el) 2015-08-05
CY1112853T1 (el) 2016-02-10
IL171928A0 (en) 2006-04-10
EP1656346A1 (en) 2006-05-17
KR101067586B1 (ko) 2011-09-27
IS2722B (is) 2011-03-15
HRP20090281T1 (en) 2009-06-30
PL1656346T3 (pl) 2009-07-31
ES2322650T3 (es) 2009-06-24
TW200510301A (en) 2005-03-16
PT2025670E (pt) 2011-05-24
CA2526866C (en) 2012-10-16
KR20110051297A (ko) 2011-05-17
KR20060015303A (ko) 2006-02-16
ATE552243T1 (de) 2012-04-15
DK1656346T3 (da) 2009-06-15
IS8920A (is) 2010-08-09
US20120178764A1 (en) 2012-07-12
TWI328004B (en) 2010-08-01
DE602004020072D1 (de) 2009-04-30
US20090163518A1 (en) 2009-06-25
RU2361860C2 (ru) 2009-07-20
CN1795174B (zh) 2011-09-28
IL171928A (en) 2011-06-30
HRP20110359T1 (hr) 2011-06-30
SE0301569D0 (sv) 2003-05-27
ES2382606T3 (es) 2012-06-11
SI1656346T1 (sl) 2009-08-31
EP2025670A1 (en) 2009-02-18
AU2004242624B2 (en) 2008-03-13
CN102391171A (zh) 2012-03-28
KR101067535B1 (ko) 2011-09-27
HK1126773A1 (es) 2009-09-11
SE0302305D0 (sv) 2003-08-27
JP2007501269A (ja) 2007-01-25
EP2281815A1 (en) 2011-02-09
EP1656346B1 (en) 2009-03-18
HK1149563A1 (es) 2011-10-07
PL2025670T3 (pl) 2011-07-29
HK1090635A1 (en) 2006-12-29
CY1109104T1 (el) 2014-07-02
ATE425965T1 (de) 2009-04-15
NO20056130L (no) 2006-02-27

Similar Documents

Publication Publication Date Title
CO5630030A2 (es) Acido 4-(acetilamino)-3-{(4-clorofenil)tio}-2-metil-1h-indol-1-acetico y composicion farmaceutica que lo contiene
CO5631431A2 (es) Indoles sustituidos novedosos
AR039933A1 (es) Indoles sustituidos para tratamiento de desordenes respiratorios
AR045462A1 (es) DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
CO5680430A2 (es) Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis
AR040498A1 (es) Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias
ES2436020T3 (es) Derivados de sulfonamida sustituidos
AR050267A1 (es) Derivados de urea ciclicos sustituidos con heterociclo, su preparacion y su uso farmaceutico como inhibidores de quinasa
AR041661A1 (es) Compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos procesos para su preparacion y composiciones farmaceuticas que lo contienen
AR064414A1 (es) Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que
AR055359A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR035854A1 (es) Compuestos derivados de piridopirimidina y naftiridina, su uso, un procedimiento para prepararlos, una composicion que los comprende, compuestos intermediarios y un proceso para preparar un compuesto sulfuro
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR054882A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
PE20030969A1 (es) Compuestos heterociclicos, activos inhibidores de beta-lactamasas
RS51650B (en) KINUCLIDINE DERIVATIVES (HETERO) arylcycloheptanecarboxylic acids as antagonists of muscarinic receptor
RS51471B (en) BIPHYNYLOXYXIC ACID DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
AR050181A1 (es) Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa
EA200800285A1 (ru) Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR064258A1 (es) Inhibidores macrociclicos del virus de hepatitis c

Legal Events

Date Code Title Description
FG Application granted